<DOC>
	<DOCNO>NCT03044587</DOCNO>
	<brief_summary>AIO-YMO/HEP-0315 ( NIFE ) open label , non-comparative , randomize , multicenter phase II trial</brief_summary>
	<brief_title>Nal-IRI With 5-fluorouracil ( 5-FU ) Leucovorin Gemcitabine Plus Cisplatin Advanced Biliary-tract Cancer</brief_title>
	<detailed_description>The primary objective determine whether combination 5-FU nal-IRI prolongs progression-free survival patient locally advance metastatic adenocarcinoma biliary tract</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Written inform consent incl . participation translational research locallyrequired authorization ( EU Data Privacy Directive EU ) obtain subject prior performing protocolrelated procedure , include screen evaluation 2 . Age ≥ 18 year time study entry 3 . Histologically confirm , nonresectable , locally advanced metastatic adenocarcinoma intrahepatic extrahepatic biliary tract 4 . Protocolspecific stag guideline observe nonresectability confirm local tumor board 5 . Measurable assessable disease accord RECIST 1.1 6 . ECOG performance status 01 7 . Life expectancy 3 month 8 . If applicable , adequately treat biliary tract obstruction study entry total bilirubin concentration ≤ 2 x ULN 9 . Adequate blood count , liverenzymes , renal function : White blood cell count ≥ 3.5 x 10^6/mL Platelet count ≥ 100 x 10^9/L ( &gt; 100,000 per mm3 ) AST ( SGOT ) /ALT ( SGPT ) ≤ 5 x institutional upper limit normal Serum Creatinine ≤ 1.5 x ULN calculate glomerular filtration rate ≥ 30 mL per minute 10 . Patients receive therapeutic anticoagulation must INR &lt; 1.5 ULN PTT &lt; 1.5 ULN within 7 day prior randomization . The use full dose anticoagulant allow long INR PTT within therapeutic limit ( accord medical standard institution ) patient stable dose anticoagulant least three week time randomization 11 . No prior palliative chemotherapy biliary tract cancer 12 . No adjuvant treatment within 6 month prior study entry 13 . Subject willing able comply protocol duration study include undergoing treatment schedule visit examination include follow . 1 . Active uncontrolled infection , chronic infectious disease , immune deficiency syndromes 2 . Premalignant hematologic disorder , e.g . myelodysplastic syndrome 3 . Clinically significant cardiovascular disease ( incl . myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) within 6 month enrollment 4 . Prior ( &gt; 5 year ) concurrent malignancy ( biliarytract cancer ) either progress require active treatment . Exceptions : basal cell cancer skin , preinvasive cancer cervix , T1a T1b prostate carcinoma , superficial bladder tumor [ Ta , Tis T1 ] . 5 . Preexisting lung disease 6 . History clinical evidence CNS metastases Exceptions : Subjects complete local therapy meet follow criterion : 1. asymptomatic 2. requirement steroid 6 week prior start study treatment . Screening CNS imaging ( CT MRI ) require clinically indicated subject history CNS metastases 7 . History hypersensitivity study drug constituent product 8 . Allogeneic transplantation require immunosuppressive therapy major immunosuppressive therapy 9 . Severe nonhealing wound , ulcer bone fraction 10 . Evidence bleed diathesis coagulopathy 11 . Major surgical procedure , except open biopsy , significant traumatic injury within 28 day prior randomization , anticipation need major surgical procedure course study except surgery central intravenous line placement chemotherapy administration . 12 . Medication know interfere agent apply trial . 13 . Female subject pregnant , breastfeed male female patient reproductive potential employ effective method birth control ( failure rate le 1 % per year ) . [ Acceptable method contraception : implant , injectable contraceptive , combine oral contraceptive , intrauterine pessary ( hormonal device ) , sexual abstinence vasectomy partner ] . Women childbearing potential must negative pregnancy test ( serum βHCG ) Screening . 14 . Known GilbertMeulengracht syndrome 15 . Known chronic hypoacusis , tinnitus vertigo 16 . Any condition comorbidity , opinion investigator , would interfere evaluation study treatment interpretation patient safety study result 17 . Participation another clinical study investigational product last 30 day inclusion 7 halflifes previously use trial medication , whichever long duration . 18 . Previous enrollment randomization present study ( include screen failure ) . 19 . Any chemotherapy study start 20 . Involvement plan and/or conduct study 21 . Patient might dependent sponsor , site investigator 22 . Patient incarcerate involuntarily institutionalize court order authority . 23 . Patients unable consent understand nature , significance implication clinical trial therefore form rational intention light fact .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Biliary Tract Cancer</keyword>
	<keyword>NaI-IRI</keyword>
</DOC>